%20(1).svg)
Executive Interview: Scaling Complex Orals to Launch
Kurt Nielsen, Ph.D., talks with Dan Smithey, Ph.D., CEO of Serán Bioscience, about oral drug innovation, large language models, complexity, and how flexibility can create new pathways to reach market quickly.
Key Takeaways:
• Complexity is the New Norm: Drug developers must adapt to working with complex molecules rather than expecting to return to simpler structures
• Technology and experience are the Enablers: Automation, AI/ML and real-time analysis by experienced scientific and engineering teams are not just advantages, but essential to tackle these challenges
• Early Assessment is Key: Assessing “drugability” and developing novel formulations early in pre-clinical development is crucial for maximizing a drug's potential
About Serán
Serán BioScience, LLC, is a science-driven Drug Development Partner, recognized as a world leader in drug development. Utilizing a foundation of physical and chemical science, Serán designs robust formulations and engineered solutions to some of the industry's toughest drug product problems. Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product. Serán’s team has decades of experience developing complex drug molecules into enabling medicines. With every addition to our team, we further our commitment to our clients’ success. From preclinical to GMP and beyond, Serán is here to support you and your drug product every step of the way.
For more information, visit www.Seranbio.com or email us at hello@seranbio.com.
Contact
Serán BioScience, LLC
63047 Layton Ave, Bend, OR 97701 USA
www.seranbio.com
.svg)